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Edited by Miguel De la RosaAbstract The mycobacterial lipoglycans, lipomannan (LM)
and lipoarabinomannan (LAM), regulate host defence mecha-
nisms through their interaction with pattern recognition recep-
tors such as Toll-like receptors (TLRs). We have developed a
surface plasmon resonance assay to analyse the molecular basis
for the recognition of Mycobacterium kansasii LM or LAM, by
immobilized CD14 and LPS-binding protein (LBP) both being
capable to promote presentation of bacterial glycolipids to
TLRs. The aﬃnity of either LM/LAM was higher to CD14 than
to LBP. Kinetic and Scatchard analyses were consistent with a
model involving a single class of binding sites. These interactions
required the lipidic anchor, but not the carbohydrate domains, of
LM or LAM. We also provide evidence that addition of recom-
binant LBP enhanced the stimulatory eﬀect of LM or LAM on
matrix metalloproteinase-9 expression and secretion in macro-
phages, through a TLR1/TLR2-dependent mechanism.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphatidyl-myo-inositol mannosides (PIMs) and their
multiglycosylated counterparts, lipomannan (LM) and lipo-
arabinomannan (LAM), are complex lipoglycans that are
ubiquitously found in the envelopes of all mycobacterial spe-
cies. PIMs, LM, and LAM all share a conserved mannosyl-Abbreviations: LM, lipomannan; LAM, lipoarabinomannan; LBP, L-
PS-binding protein; MMP, matrix metalloproteinase; LPS, lipopoly-
saccharide; MPI, mannosyl-phosphatidyl-myo-inositol; TLR, Toll-like
receptor; PIM2, phosphatidyl-myo-inositol dimannoside; PIM, phos-
phatidyl-myo-inositol mannoside; DC-SIGN, dendritic cell-speciﬁc
ICAM-3 grabbing non-integrin; AMannan, arabinomannan; P-AMan-
nan, phosphorylated arabinomannan; Mannan, mannan; P-Mannan,
phosphorylated mannan; PRR, pattern recognition receptor; SPR,
surface plasmon resonance technology; RU, resonance unit; Requ,
equilibrium response values
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doi:10.1016/j.febslet.2007.02.056phosphatidyl-myo-inositol (MPI) domain that presumably an-
chors these structures into the plasma membrane. In addition
to the MPI, LAM possesses a mannan core with a branched
arabinan polymer and, in some cases, capping motifs decorate
the termini of the branched arabinan [1,2]. LAM can be clas-
siﬁed into three major structural families according to the
capping motifs present on the non-reducing termini of the
arabinosyl side-chains. The arabinan termini in the pathogenic
strains Mycobacterium tuberculosis, M. leprae, M. avium, M.
bovis BCG and M. kansasii are modiﬁed with mannose caps
[3–8] resulting in molecules designated ManLAM, whereas in
the fast-growing non-pathogenic species branches of the termi-
nal arabinan are terminated by inositol phosphate-caps [2,7],
characterising the PILAM family. A third LAM family, desig-
nated AraLAM, identiﬁed in M. chelonae comprises a LAM
molecule devoid of both the manno-oligosaccharide and inosi-
tol phosphate caps [9].
These lipoglycans play important roles in the physiology of
the bacterium and modulate the innate immune system
through their binding to various pattern recognition receptors
(PRRs), including Toll-like receptor-2 (TLR2), CD14, man-
nose receptor and dendritic cell-speciﬁc ICAM-3 grabbing
non-integrin (DC-SIGN) [10–16].
LM and PILAM induce, via a TLR2-dependent signalling
mechanism, the expression of proinﬂammatory cytokines
[17–19] and the synthesis of matrix metalloproteinase protein
(MMP-9) [20]. MMP-9 is involved in extracellular matrix
remodelling, leukocyte migration at infectious sites and the
granuloma formation during M. tuberculosis infection [21].
Recent work also demonstrated that LM induces granuloma
macrophages fusion through a mechanism involving TLR2
[22]. Furthermore, both DC-SIGN and mannose receptor were
shown to participate in the anti-inﬂammatory response elicited
by ManLAM [14,15,23,24]. Although it is now admitted that
TLR2 is required for cell activation by LM and LAM, numer-
ous studies suggested that CD14 and LPS-binding protein
(LBP) may be associated with TLR to increase the responsive-
ness of cells to these mycobacterial glycolipids [25–29]. LBP is
an acute-phase serum protein which disaggregates and trans-
fers bacterial glycolipids to CD14 [29,30]. CD14 is a glycopro-
tein which exists in two forms, either bound to the membrane
of monocytes/macrophages by a GPI anchor (mCD14) or sol-
uble in plasma (sCD14) [31]. Anti-CD14 antibodies decreasedblished by Elsevier B.V. All rights reserved.
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phages [17,20], whereas a CD14/TLR2 cotransfection or the
addition of sCD14 to cells, enhanced the biological responses
[25–27]. However, despite the suggested role of CD14 and
LBP in the presentation of LM/LAM to TLR2, no informa-
tion is available with regard to the binding parameters and
the nature of the structural domains of these lipoglycans that
interact with CD14 and LBP.
Herein, we determined, through the use of surface plasmon
resonance technology (SPR), the binding aﬃnity and kinetic
parameters of LM and ManLAM isolated from M. kansasii,
to immobilized human recombinant CD14 and LBP. In order
to deﬁne the relative contribution of the lipidic or carbohy-
drate domains in the interactions with CD14 or LBP, we also
analysed the binding properties of various structurally related
lipoglycans isolated from M. kansasii. These include PIM2
(Fig. 1a), which is a direct biosynthetic precursors of LM, as
well as as a representative panel of non-acylated derivatives
of LM and LAM such as phosphorylated arabinomannan
(P-AMannan), phosphorylated mannan (P-Mannan), arabino-
mannan (AMannan) and mannan (Mannan) (Fig. 1b). Our
work not only suggests that the lipidic aglycone anchor of
LM or ManLAM is essential for interacting with CD14 and
LBP, but also that these interactions trigger TLR1/TLR2-
dependent biological eﬀects, as demonstrated by MMP-9
expression in the THP-1 macrophagic cell line.Fig. 1. Schematic representation of the mycobacterial lipoglycans and
carbohydrate molecules puriﬁed from M. kansasii and used in this
study. (a) Acylated glycoconjugates: ManLAM, LM, PIM2 and (b)
non-acylated variants of LM/LAM: P-AMannan, P-Mannan, AMan-
nan and Mannan.2. Materials and methods
2.1. Reagents
RPMI 1640 medium and L-glutamine were purchased from Invitro-
gen (Cergy Pontoise, France) and foetal calf serum (FCS) from Euro-
bio (Les Ulis, France). Dulbecco’s phosphate buﬀered saline with
calcium and magnesium (PBS) was from Sigma (St. Louis, MO).
1,25-Dihydroxy-vitamin D3 was purchased from Calbiochem (Darms-
tadt, Germany) and the apyrogen water was from Cooper (Melun,
France). Human recombinant LBP and CD14 were from Biometec
(Greifswald, Germany). Various neutralizing anti-receptor mouse
monoclonal antibodies, known to inhibit biological activities of micro-
bial products, were provided without azide: IgG1 anti-CD14 (clone
MEM-18) and IgG2a anti-TLR2 (clone TL2-1) were from HBT
(Uden, The Netherlands), IgG1j anti-TLR1 (clone GD2.F4), IgG2aj
anti-TLR4 (clone HTA 125) and isotype control antibodies were from
BD Biosciences (San Diego, CA), whereas the IgG1j anti-mannose
receptor (clone 19) was purchased from BD Pharmingen (San Diego,
CA). Quantikine human MMP-9 protein detection kit was purchased
from R&D systems (Minneapolis, MN).
2.2. Extraction and puriﬁcation of lipoglycans
LM, LAM and PIM2 (phosphatidyl-myo-inositol dimannoside)
from M. kansasii (PHRI 901, a clinical strain isolated from a HIV-po-
sitive patient) were puriﬁed by successive detergent and phenol extrac-
tions, separated by gel ﬁltration on a Sephacryl 200 column in Tris/
deoxycholate buﬀer and extensively dialyzed as described previously
[3,9]. The average molecular masses of these molecules were estimated
at approximately 16000 and 7000 Da for ManLAM and LM, respec-
tively [3]. Purity of all preparations was assessed through gas chroma-
tography/mass spectrometry (GC/MS) routine experiments, NMR
spectra and SDS–PAGE following silver nitrate staining. No contam-
inating lipoproteins lipopeptides could be detected. The endotoxin
content of each preparation was <20 pg LPS/10 lg, as determined by
the chromogenic Limulus lysate assay (QCL1000; BioWhittaker,
Walkersville, MD).
Mannan, P-Mannan, AMannan and P-AMannan were extracted
from detergent depleted phase of M. kansasii after phase partitioning
with Triton X-114 and separated by successive gel chromatographies
as already described [31].2.3. Direct binding assays by surface plasmon resonance
Binding analyses were performed on a BIAcore 3000 instrument
(Biacore Ab, Uppsala, Sweden). This methodology is based on SPR,
which enables a real-time detection of molecular interactions by mon-
itoring refractive index changes caused by alteration in mass on the
optical sensor. Human recombinant CD14 (or LBP) was covalently
coupled to a CM5 (carboxymethylated) sensor chip, using a standard
Amine Immobilization kit supplied by the manufacturer (Biacore).
Brieﬂy, after activation of the chip surface with N-hydroxysuccinimide
and dimethylaminopropyl-N 0-ethylcarbodiimide, 65 ll of CD14 or
LBP at 20 lg/ml, diluted in 10 mM sodium acetate, pH 4.8, were
injected at 5 ll/min. The remaining free sites were inactivated by 1 M
ethanolamine, pH 8.5. Amounts of 3800–4000 RU (resonance unit)
and 1800–2000 RU of LBP and CD14, respectively, were immobilized
under these conditions, with 1 RU corresponding to an immobilized
protein concentration of 1 pg/mm2. Immobilized proteins were used
within 48 h for providing maximal reproducibility of the results.
Increasing concentrations of each mycobacterial glycoconjugate
(PIM2, LM, LAM, Mannan, AMannan, P-Mannan, P-AMannan),
ranging from 20 lg/ml to 160 lg/ml in PBS containing calcium and
magnesium (Gibco) were injected at a ﬂow rate of 10 ll/min. Following
injection of 65 ll of sample at 25 C, the formed complexes were
allowed to dissociate in PBS. Regeneration of the sensor chip surface
was performed by short pulses of 90% ethylene-glycol, at a ﬂow rate
of 30 ll/min and repeated washes with PBS. Control ﬂow-cells were
obtained by injection of the respective analyte solutions on a chip sub-
mitted to the activation-deactivation coupling protocol. Results are
represented as sensorgrams, expressed as a response in resonance units,
which is proportional to the quantity of analyte bound to immobilized
CD14 or LBP. Data were analysed using the Biacore 3.0 evaluation
software. The measured association (kon) and dissociation (koﬀ) rate
constants allowed the determination of the equilibrium dissociation
constant KD, through the ratio koﬀ/kon. KD was also determined from
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the time of injection, the equilibrium response values (Requ) were cal-
culated from the association phases obtained with increasing concen-
trations of analytes.
2.4. Cells
Human pro-monocytic leukaemia THP-1 cells (ECACC no.
88081201) were grown in RPMI 1640 supplemented with 10% FCS,
2 mM L-glutamine and 2· 105 M b-mercaptoethanol in a 5% CO2-
air humidiﬁed atmosphere at 37 C. Viability of cells was over 96%
as determined by trypan blue dye exclusion.2.5. Eﬀect of LBP on the MMP-9 gene expression
5 · 106 diﬀerentiated THP-1 cells were incubated in 12-well plates in
RPMI/glutamine serum-free medium with various lipoglycan concen-
trations in the absence or presence of 0.2 lg/ml of recombinant human
LBP. After 24 h of incubation at 37 C, total RNA was extracted
and puriﬁed from activated cells using the Nucleospin RNA II kit
(Macherey-Nagel, Du¨ren, Germany), according to the manufacturer’s
instructions. Reverse transcription (RT) and PCR ampliﬁcation
were performed as described previously [20] by using primer pairs
(Eurogentec) designed for the speciﬁc detection of human MMP-9
[5 0-GCGGAGATTGGGAACCAGCTGTA-3 0 (forward primer) and
5 0-GACG- CGCCTGTGTACACCCACA-3 0 (reverse primer)] at
68 C for 23 cycles. GAPDH was used as an internal reference, since
this gene is constitutively expressed in diﬀerentiated THP-1 cells
[5 0-CTCTGCC- CCCTCTGCTGATGC-3 0 (forward primer) and 5 0-
CCATCACGCCACAGTTTCCCG-3 0 (reverse primer) (69 C, 17
cycles)]. PCR products (208 and 256 bp for MMP-9 and GAPDH,
respectively) were separated by electrophoresis on a 2% agarose gel
and visualized by ethidium bromide staining under ultraviolet light
illumination. Gels were then analysed by computerized densitometric
imaging with the Bio-Rad GelDoc analysis system and Quantity One
software, version 4.1.0 (Bio-Rad, Italy).
In order to identify receptors which mediate MMP-9 expression in-
duced by LAM, diﬀerentiated THP-1 cells were pre-treated for 30 min
at 37 C with 10 lg/ml of cell surface neutralizing monoclonal antibod-
ies (anti-CD14, anti-TLR1, anti-TLR2, anti-TLR4, and anti-mannose
receptor). Cells were then stimulated for 24 h to allow MMP-9 expres-
sion by adding 1 lg/ml of ManLAM in the presence of 0.2 lg/ml of
LBP. The corresponding isotype controls were used as negative con-
trols.2.6. Quantiﬁcation of MMP-9 secretion by ELISA
2 · 105 diﬀerentiated THP-1 cells were grown in 96-well plastic cul-
ture plates for 48 h, in RPMI supplemented with glutamine, in the
presence of increasing concentrations of puriﬁed LM or ManLAM,
in the absence or presence of 0.2 lg/ml of human recombinant LBP.
Quantiﬁcation of total MMP-9 (pro and active forms) released in the
cell culture supernatant was performed by enzyme-linked immunosor-
bent assay (ELISA), as previously described [20]. Statistical signiﬁ-
cance of diﬀerences was calculated by using the Student’s t test.
Values of P < 0.05 were considered to be signiﬁcant.3. Results
3.1. SPR analyses of LM and ManLAM binding to LBP and
CD14
The ability of LM and ManLAM puriﬁed from M. kansasii
to bind to immobilized human recombinant LBP (Fig. 2a and
c) and sCD14 (Fig. 2b and d) was investigated using the SPR
technology, as described in Section 2. The molecular associa-
tion and dissociation phases were illustrated by sensorgrams
obtained for each concentration of glycolipids, after substrac-
tion of the non-speciﬁc binding to a sensor chip control cell. As
shown in Fig. 2, injection of increasing concentrations of LM
(Fig. 2a and b) and ManLAM (Fig. 2c and d) provided a dose-
dependent response, consistent with a speciﬁc interaction withCD14 or LBP. Speciﬁcity of the interaction of glycolipids with
LBP was also conﬁrmed by using the properties of denatur-
ation of the protein by rapid changes of pH, as recommended
by the manufacturer. After passage of 30 ll of HCl 0.1 M (pH
2) for 3 min on the LBP-containing ﬂow cell, no binding of gly-
colipids to the protein could be observed (not shown). With
regard to CD14, the binding speciﬁcity was assessed by its
inability to interact with glycolipids after 4 days of SPR exper-
iments at 20 C (data not shown). Additionally, a chip cell
coated with bovine serum albumin was used as a control.
Analysis of the sensorgrams with the BIA evaluation 3.0 sof-
ware indicated that binding of LM and ManLAM to either
CD14 or LBP were monophasic and ﬁtted with the langmuir
binding model. The association rate constants (kon) calculated
from the binding of LM and ManLAM to CD14 were similar
to the kon measured for the binding to LBP (Table 1). The dis-
sociation of analytes from all the complexes in the presence of
PBS was very slow. Various buﬀers were tested to regenerate
sensor chip. Whereas saline buﬀer (pH 7.2) containing 1 M
of NaCl with EDTA or Glycine/HCl (pH 5) were uneﬃcient,
ethylene glycol (90% (v/v) in PBS) was required to release
bound LM and ManLAM, suggesting occurrence of hydro-
phobic interactions. Furthermore, the equilibrium dissociation
constants (KD) calculated from kinetic rate constants (koﬀ/kon
ratio) revealed higher binding aﬃnity of these glycolipids to
CD14 than to LBP: KD were 2.89 · 108 M and 7.52 ·
109 M for LM and ManLAM with CD14, as compared to
1.84 · 107 M and 4.25 · 108 M, respectively, with LBP.
The KD were also determined by Scatchard plot analysis
(Fig. 2, insets) and are consistent with the kinetically-deter-
mined values, as illustrated in Table 1. The linear Scatchard
representations are suggestive of a single class of binding site
in CD14 or LBP for both LM and ManLAM.
3.2. Identiﬁcation of the lipoglycan structural motifs required
for the interaction with CD14 and LBP
To decipher the motifs of LM/ManLAM important for liga-
tion to CD14 and LBP, we took advantage of using a vast
panel of structural variants of LM and LAM which were iden-
tiﬁed and isolated during the LM/LAM puriﬁcation process.
These natural cell wall-associated glycoconjugates only diﬀer
from the parental LM and LAMmolecules by lacking the fatty
acids attached to the MPI anchor, hence their names P-Man-
nan and P-AMannan (Fig. 1b) [31]. Mannan and AMannan
molecules, respectively corresponding to LM and LAM lack-
ing the entire MPI anchors, were also added in our experi-
ments.
First, ligation of PIM2, known as direct precursors of LM,
to the glycoproteins has also been evaluated, as shown in
Fig. 3. PIM2 bound to LBP (a) and CD14 (b) with similar
KD of 4.38 · 107 M and 7.54 · 107 M (Table 1), respectively.
However, the aﬃnity of PIM2 was lower than to LM or Man-
LAM with respect to CD14 binding. PIM2 appeared to disso-
ciate more rapidly from CD14 or LBP complexes than LM and
ManLAM.
In contrast, no signiﬁcant interactions of AMannan or Man-
nan were detected with respect to LBP or CD14 binding
(Fig. 3c and d), even when higher concentrations were used
(up to 80 lg/ml). Because these polysaccharides correspond
to LAM and LM devoid of MPI anchors, the lack of interac-
tions could be attributed either to the absence of phosphatidyl-
inositol or to the absence of fatty acids bound to the MPI
Fig. 2. Binding of LM and ManLAM to LBP and CD14 by SPR analysis. LBP (a and c) and CD14 (b and d) were immobilized on a CM5 sensor
chip and 65 ll of LM (a and b) or ManLAM (c and d) were injected at the indicated concentrations at a ﬂow rate of 10 ll/min. Dissociation of
complexes was then performed in PBS. Each sensorgram was obtained by substracting unspeciﬁc binding of lipoglycans to the sensor chip control
cell. Scatchard plot analyses of the sensorgram data are shown in insets. These results are representative of at least four independent experiments with
similar results.
Table 1
Binding kinetic parameters for the interaction of mycobacterial
lipoglycans with LBP and CD14
kon
(1/Ms)
koﬀ
(1/s)
KD (M)
(koﬀ/kon)
KD
(M)(Scatchard)
Binding to LBP
LM 263 4.83e5 1.84e7 1.99e7
ManLAM 680 2.89e5 4.25e8 3.27e8
PIM2 542 2.37e4 4.38e7 1.07e7
Binding to CD14
LM 318 9.17e6 2.89e8 4.39e8
ManLAM 627 4.73e6 7.52e9 1.56e8
PIM2 839 6.33e4 7.54e7 7.50e7
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we analysed the binding properties of P-AMannan and
P-Mannan (only diﬀering from LAM and LM by the absence
of the two fatty acids of the MPI anchor [31]). As shown in
Fig. 3, P-AMannan/AMannan and P-Mannan/Mannan be-
have similarly, with no signiﬁcant binding to LBP or CD14.
Together, these results indicate that the fatty acyl chains of
the MPI anchor, but neither the carbohydrate domains northe phosphatidyl inositol group of LM/LAM, are required
for ligation to CD14 or LBP.
3.3. Eﬀect of LBP on MMP-9 expression induced by LM and
LAM in macrophages
LM has been described as a potent pro-inﬂammatory-induc-
ing factor [2,11,17–19] through induction of pro-inﬂammatory
cytokines such as IL-8, TNF-a or IL-12 [17–19] or MMP-9
expression [20]. LM-dependent expression of MMP-9 has been
demonstrated in macrophage-like diﬀerentiated THP-1 cells
that co-express both TLR2 and CD14 [20]. However, this eﬀect
has not been reported yet for ManLAM. Since the biological
activity of various bacterial glycolipids is enhanced in presence
of LBP [29,30], and because our results indicate that LM and
ManLAM physically interact with LBP, we investigated the
ability of LBP to modulate the activity of LM and ManLAM
in relation with MMP-9 expression, both at a transcriptional
and a translational level.
As shown in Fig. 4b, incubation of diﬀerentiated THP-1 cells
with increasing concentrations of LM stimulates the MMP-9
gene expression. Addition of 0.2 lg/ml of LBP resulted in a
reproducibly two-fold increase in MMP-9 secretion, as com-
pared to cells exposed to LM alone. Incubation with LBP
Fig. 3. Identiﬁcation of the structural motifs of LM and ManLAM required for interaction with LBP and CD14. Increasing concentrations of PIM2,
LM, ManLAM, as well as their non-acylated structural variants were passed over immobilized LBP (a) or CD14 (b), in conditions similar to those
described in Fig. 2. Binding properties of P-AMannan, P-Mannan, AMannan and Mannan (40 lg/ml) to LBP (c) and CD14 (d) were analysed by
SPR and compared to those of ManLAM (20 lg/ml). Data are representative of two independent experiments with similar results.
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results suggest that, while LBP is not required for the MMP-9-
inducing activity of LM, it potentializes its eﬀect, particularly
at low concentrations. Similar results were also obtained with
PIM2 (data not shown). Indeed, expression of MMP9 mRNA
is induced in a dose-dependent manner by PIM2 and increased
in the presence of LBP.
In contrast to LM, ManLAM alone was not found to trigger
MMP-9 transcription (Fig. 4a). Only a slight increase of
MMP-9 secretion could be detected when cells were exposed
to 10 lg/ml of ManLAM (Fig. 4b). Nevertheless, LBP strongly
enhanced the capacity of ManLAM to induce both MMP-9
mRNA expression (Fig. 4a) and MMP-9 secretion (Fig. 4b).
These results clearly emphasize the importance of LBP in the
MMP-9 expression by ManLAM. However, it is noteworthy
than the amount of MMP-9 measured following LAM-LBP
stimulation was reproducibly lower than that obtained upon
stimulation with LM-LBP.
Taken together, these results underscore the potency of LBP
to enhance MMP-9 gene expression and MMP-9 secretion in-
duced by LM and LAM, presumably due to its role as a lipo-
glycan-presenting molecule to the macrophage cell surface
receptors.
The involvement of TLR2/TLR1 and CD14, but not TLR4,
in MMP-9 synthesis after stimulation of macrophages with
LM from M. kansasii has been previously described [20]. Riv-
era-Marrero et al. [24] also showed that a speciﬁc anti-man-
nose receptor antibody blocked the induction of MMP-9 byManLAM fromM. tuberculosis. Therefore, in order to identify
receptors recognizing ManLAM-LBP complexes and partici-
pating in signalling events leading to MMP-9 expression, we
evaluated the inhibitory eﬀect of various neutralizing anti-
receptor antibodies on MMP-9 synthesis. As illustrated in
Fig. 5, MMP-9 gene expression induced by ManLAM plus
LBP was inhibited by 72% with anti-TLR1 (clone GD2.F4),
34% with anti-TLR2 (clone TL2-1) and 64% with anti-CD14
(clone MEM-18) antibodies, whereas anti-TLR4 (clone HTA
125) appeared ineﬃcient. The contribution of anti-mannose
receptor antibodies (clone 19) to reduce MMP-9 expression
(16%) was not signiﬁcant (P > 0.05). The corresponding con-
trol isotype antibodies were also included in the experiment
and no signiﬁcant inhibition was detected (not shown). Alto-
gether, these results suggest the major participation of
TLR1/TLR2 and CD14 in the signalling pathway leading to
MMP-9 induction from diﬀerentiated THP-1 cells activated
by ManLAM-LBP complexes.4. Discussion
This study deﬁnes, for the ﬁrst time, the binding kinetics of
LM and ManLAM to immobilized CD14 and LBP and iden-
tiﬁes the structural motifs of LM/LAM involved in the recog-
nition.
CD14 and LBP were reported to interact with a very wide
range of bacterial compounds which are, for the majority,
Fig. 4. Eﬀect of LBP on MMP-9 expression induced by LM or
ManLAM. Various concentrations of LM or ManLAM were added
alone or supplemented with 0.2 lg/ml of puriﬁed human recombinant
LBP in serum-free medium. (a) MMP-9 gene expression was
determined by RT-PCR analysis after 24 h of induction. RT-PCR
data are representative of three independent experiments with similar
results. GAPDH was used as a constitutively-expressed marker. (b)
MMP-9 secretion levels in supernatants of activated cells were
determined by ELISA after 48 h of induction. ELISA data are
expressed as the means ± S.D. of triplicate wells and are representative
of three independent experiments with similar results. The statistical
signiﬁcance of diﬀerences in comparison with untreated cells by LBP
was calculated by using Student’s t test (*indicates P < 0.001,
**P < 0.005 and ns non-signiﬁcant value P > 0.05).
Fig. 5. Inhibition of MMP-9 expression induced by ManLAM-LBP
complexes by speciﬁc PRRs. Diﬀerentiated THP-1 cells were pre-
treated with 10 lg/ml of either anti-CD14, anti-TLR1, anti-TLR2,
anti-mannose receptor or control isotype antibodies for 30 min at
37 C, prior to the addition of ManLAM (1 lg/ml) plus LBP (0.2 lg/
ml). Control cells were incubated in the absence of antibodies. After
24 h of incubation, expression levels of MMP-9 and GAPDH mRNA
were determined by RT-PCR analysis as described in Section 2. The
ratios of ﬂuorescence intensities of MMP-9 and GAPDH PCR
products were calculated and results are expressed as percentages of
the MMP-9/GAPDH ratio obtained with ManLAM in the presence of
LBP. The ratio values obtained in the absence of antibodies were
arbitrarily placed at 100%. Data represent the mean values ± S.E.M. of
three independent experiments (Student’s t test to compare anti-
receptor antibodies treated cells with non-treated cells: *P < 0.001,
**P< 0.005 and ns non-signiﬁcant value P > 0.05).
1388 E. Elass et al. / FEBS Letters 581 (2007) 1383–1390amphiphilic molecules such as lipoglycans (LPS, lipoteı¨choı¨c
acid), lipopeptides [29] and glycerophospholipids [32]. While
the hydrophobic region of these various molecules is essential
in these interactions, LBP can also bind to heparin anionic gly-
cosaminoglycans [33] and CD14 exhibits lectin-like properties
[34] by interacting with peptidoglycan [35] or uronic acid poly-
mer [36]. In this study, the dissociation constants (KD) deter-
mined by SPR for the binding of LM and ManLAM to
CD14 and LBP, were close to the value previously reported
for LPS-CD14 (2.9 · 108 M) and LPS-LBP (3.5 · 109 M)
complexes [30]. We show here that these high-aﬃnity interac-
tions result from very slow association and dissociation kinet-
ics. Furthermore, structure/activity relationship studies using
natural non-acylated forms of LM and LAM (P-Mannan, P-
AMannan, Mannan and AMannan) indicated that the major
fatty acids in the glycerophosphoinositol headgroup (palmitic
acid (C16) and tuberculostearic acid (C19)) are essential for
ligation of LM or ManLAM to CD14 and LBP. The total dis-
sociation of LM/ManLAM-CD14 and LM/ManLAM-LBP
complexes in presence of detergent also supports the involve-
ment of hydrophobic interactions. This is in agreement witha recent SPR study demonstrating a direct interaction between
a triacylated lipopeptide and CM5-immobilized CD14 [37].
Furthermore, since PIM2 (that only contain a limited number
of mannose residues compared to LM or LAM) is recognized
by both CD14 and LBP glycoproteins, this suggests that the
arabinosyl and mannosyl carbohydrate domains of LM or
LAM are not required for interaction. Nevertheless, it is notice-
able that PIM2 bound to CD14 with a lower aﬃnity than LM
and ManLAM and dissociated much faster from LBP and
CD14, suggesting that whereas the carbohydrate domain is
not required for recognition, the mannan core could participate
in the stability of these complexes. Thus, the presence of addi-
tional mannose residues in LM/LAM participate in the slow
dissociation of the complexes with CD14 or LBP. Additionally,
the heterogeneity of the fatty acids attached to PIM2 may inﬂu-
ence their binding to CD14 or LBP. Indeed, LM, LAM and
PIM2 contain a mixture of di- and triacyls. Interestingly, triacy-
lated, but not diacylated, lipopeptides were shown to bind to
CD14 [37]. In a previous SPR study conducted to analyse the
interaction of ManLAM fromM. tuberculosis with human pul-
monary surfactant lectinic protein A (SP-A), it was shown that
both the terminal mannose capping and the fatty acids of Man-
LAM play a critical role for binding to SP-A [38]. In this par-
ticular case, the lipid moiety of ManLAM does not directly
interact with SP-A, but is rather involved in the formation of
supramolecular assemblies necessary for the multivalent bind-
ing of the 18 carbohydrate-recognition-domains (CRD) present
E. Elass et al. / FEBS Letters 581 (2007) 1383–1390 1389in this lectin.Whereas CD14 has been reported to exhibit lectin-
like properties [34], no multivalent carbohydrates binding sites
have been described. Thus, CD14 and SP-A receptors not only
diﬀer by their structures and biological functions, but also by
their physical interactions with LM and LAM.
LBP is predominantly produced in the liver but is also found
in the lung alveolar epithelial cells [39] and seems to play,
in vivo, an essential role in pulmonary innate immune re-
sponses against bacteria [40]. The serum concentration of
LBP is elevated during bacterial infections such as in tubercu-
losis [41] and patients with various inﬂammatory lung diseases
displayed elevated LBP and sCD14 concentrations in their
bronchoalveolar lavage ﬂuid [42,43]. Moreover, a recent study
demonstrated that LBP-deﬁcient mice have reduced lympho-
cyte recruitment and activation during the early stages of M.
tuberculosis infection [44]. Our results suggest that the addition
of recombinant human LBP to macrophagic THP-1 cells
potentializes MMP-9 expression/secretion induced by low con-
centrations of LM. Since mycobacterial lipoglycans are com-
plex amphipatic molecules forming micelles in aqueous
solution, we propose that LBP disaggregates these glycolipidic
complexes and promotes the transfer of monomers to TLR1/
TLR2 and CD14 receptors, thereby amplifying the cell activa-
tion signal, as reported for LPS with TLR4 [45]. Recently, Gil-
leron et al. [13] demonstrated that triacylated LM is the best
agonist of TLR2/TLR1 heterodimers, suggesting that the de-
gree of LM acylation is critical in the interaction with these
PRR and the proinﬂammatory activity of LM.
The capacity of ManLAM to upregulate MMP-9 gene
expression and inducing MMP-9 secretion was highly depen-
dent on the presence of LBP. In the absence of LBP, Man-
LAM from M. kansasii displayed no eliciting eﬀect, as it was
previously shown for the production of pro-inﬂammatory
cytokines in diﬀerentiated THP-1 cells [17,18]. Nevertheless,
MMP-9 secretion induced by ManLAM-LBP complexes was
lower than with LM-LBP complexes. The use of neutralizing
antibodies demonstrated that this stimulatory eﬀect of Man-
LAM-LBP complexes is dependent on TLR1/TLR2 and
CD14-signalling pathways. Together, these observations lead
us to hypothesize that the physical interaction between Man-
LAM and LBP induces conformational changes of ManLAM
molecules that would allow the binding of this lipoglycan to
TLR1/TLR2. LBP may dissociate LAM molecules from bulky
aggregates, thus promoting binding to TLR and CD14 recep-
tors. This is in agreement with a recent work demonstrating
self-aggregation of ManLAM by transmission electron micros-
copy and revealing a supra-molecular structural organization
[46]. These authors proposed than the critical micellar concen-
tration may modulate the biological activities of these lipogly-
cans.
In conclusion, our results clearly indicate that LM and LAM
from M. kansasii are high aﬃnity ligands for both CD14 and
LBP, which in turn can present these lipoglycans to TLR1/
TLR2 receptors. Although their lipidic anchors seem to repre-
sent the major recognition sites for binding CD14 or LBP, the
glycan domains may represent modulatory domains. A com-
plete understanding of the molecular mechanisms of host rec-
ognition is required and may help to improve therapeutical
strategies against mycobacterial infections.
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